Sign In
Buy LRMR
$4.11
+0.130 (+3.27%)
At Close: Aug 04, 2026
BALA CYNWYD, Pa., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseas
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
05:49pm, Friday, 03'rd Jan 2025
Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels f
What's Going On With Larimar Therapeutics Stock On Tuesday?
01:39pm, Tuesday, 17'th Dec 2024
On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administer
Market 'misinterpreting' Larimar data, selloff 'overdone,' says Citi
03:21pm, Monday, 16'th Dec 2024
Citi analyst Samantha Semenkow notes Larimar Therapeutics announced initial data from the ongoing long-term Open Label Extension study evaluating daily subcutaneous injections of 25 mg of nomlabofusp
Why Is Larimar Therapeutics Stock Trading Lower On Monday?
12:17pm, Monday, 16'th Dec 2024
On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered
BALA CYNWYD, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare dise
Zacks Industry Outlook Madrigal, Corcept, Catalyst Larimar and Theravance
08:51am, Monday, 11'th Nov 2024
Madrigal, Corcept, Catalyst Larimar and Theravance have been highlighted in this Industry Outlook article.
5 Small Drug Stocks to Buy as Trump Gets Re-Elected
08:21am, Friday, 08'th Nov 2024
Innovation is at its peak for the Zacks Medical-Drugs industry. MDGL, CORT, CPRX, LRMR and TBPH may prove to be good additions to one's portfolio.
Wall Street Analysts Think Larimar (LRMR) Could Surge 192.89%: Read This Before Placing a Bet
10:55am, Monday, 04'th Nov 2024
The mean of analysts' price targets for Larimar (LRMR) points to a 192.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analyst
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
07:00am, Wednesday, 30'th Oct 2024
BALA CYNWYD, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments fo
Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock
02:59pm, Wednesday, 16'th Oct 2024
Oppenheimer has initiated coverage on Larimar Therapeutics LRMR, a clinical-stage biotechnology company focused on developing treatments for rare diseases.
Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
09:28pm, Sunday, 06'th Oct 2024
Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a sol
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
07:00am, Thursday, 19'th Sep 2024
BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disea
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
04:05pm, Thursday, 30'th May 2024
BALA CYNWYD, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare disease
2 Potentially High-Reward Growth Stocks to Buy Right Now
08:45am, Wednesday, 29'th May 2024
Growth stocks have been the U.S. market's primary value driver since 2008. Biotechnology equities, however, have been in a wilderness period since the central bank ramped up interest rates.
